745041-80-9

Upstream product

• 2433-96-7 tricosanoic acid 
• 745041-72-9 (2S,3S,4R)-2-amino-3,4-O-isopropylidene-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-1,3,4-nonanetriol 
• 570414-15-2 (2R,3R,4R)-2-O-methanesulfonyl-1,2,3,4-nonanetetrol 
• 570414-16-3 (2S,3S,4R)-2-azido-nonane-1,3,4-triol 
• 942623-41-8 C₁₇H₂₆O₆S 
• 956028-66-3 C₁₆H₂₄O₄ 
• 918867-23-9 4,5-anhydro-1,3-O-benzylidene-D-arabitol 
• 745041-64-9 (2S,3S,4R)-2-azido-3,4-O-isopropylidene-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-1,3,4-nonanetriol 
• 745041-56-9 (2S,3S,4R)-2-azido-3,4-O-isopropylidene-1,3,4-nonanetriol 

Downstream Products

• 745042-03-9 2-tricosanoylamino-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-D-ribo-1,3,4-nonanetriol 

Relevant academic research and scientific papers

Synthesis and biological evaluation of truncated α-galactosylceramide derivatives focusing on cytokine induction profile

A series of truncated analogs of α-galactosylceramide with altered ceramide moiety was prepared, and evaluated for Th2-biased response in the context of IL-4/IFN-γ ratio. Phytosphingosine-modified analogs including cyclic, aromatic and ethereal compounds

Minimum structure requirement of immunomodulatory glycolipids for predominant Th2 cytokine induction and the discovery of non-linear phytosphingosine analogs

Analogs of immunomodulatory glycolipid OCH (2) were prepared and minimum structure requirement to exhibit equivalent profiles was disclosed. Analogs bearing non-linear hydrocarbon chain in the phytosphingosine moiety (18, 19) were shown for the first time

GLYCOLIPID DERIVATIVES, PROCESS FOR PRODUCTION OF THE SAME, INTERMEDIATES FOR SYNTHESIS THEREOF, AND PROCESS FOR PRODUCTION OF THE INTERMEDIATES

Novel glycolipid derivatives, where the substituent of the sphingosine base part is a short carbon chain alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted aryl group or substituted or unsubstituted aralkyl group and